Chargement...

Robocath receives NMPA approval for R-One robotic platform in China

9 January 2024

Rouen, France, January 9, 2024 – Robocath, a company that designs, develops and markets innovative robotic solutions to treat cardiovascular diseases, today announces the granting of a marketing authorization to distribute its R-One robotic platform in China. This was issued on December 8, by the Chinese National Medical Products Administration (NMPA); making it the first vascular robotic platform to be granted approval in China.

This approval is based in part on the outstanding results achieved in Cathbot’s multicenter clinical trial…

Learn more

Robocath performs world’s First-In-Human remote robotic coronary angioplasty between two Chinese cities 1,700 miles apart

13 December 2023

Procedure took place simultaneously in Beijing and Urumqi, carried out entirely via 5G connection with R-One™ robotic platform

Rouen, France, December 13, 2023 – Robocath, a company that designs, develops and markets innovative robotic solutions for treating cardiovascular diseases, today announces it performed a First-in-Human robotic coronary angioplasty from 1,700 miles (2,800 km) away. Two interventional cardiologists, Prof. Yundai Chen in Beijing and Prof. Yining Yang in Urumqi, the capital of the Xinjiang Uygur Autonomous Region, performed the procedure. This world-first, performed…

Learn more

Robocath demonstrates feasibility of robotic carotid stenting in ‘CARE’ clinical trial conducted at Rennes University Hospital

19 October 2023

• 100% clinical success rate: zero complications linked to robot at day 0 and day 30
• R-One™ obtained 86% technical success rate

Rouen and Rennes, France, October 19, 2023 — Robocath, a company that designs, develops and commercializes smart robotic solutions for the treatment of cardiovascular diseases, today announces the results of its ‘CARE’ clinical trial focusing on robotic carotid stenting (1). This study is the first phase in an ambitious research program launched in July…

Learn more

Robocath launches new robotic platform R-One+

16 May 2023

Rouen, France, May 16, 2023 – Robocath, a company that designs, develops and commercializes smart robotic solutions for the treatment of cardiovascular diseases, today announces the launch of its latest robotic platform – the R-One+. Robocath will showcase this new solution during the upcoming international EuroPCR conference in Paris (France), from May 16 to 19, at the company’s booth (M19, second floor). The R-One+ platform will also be presented in more detail during a dedicated session ‘Robotic PCI: real-life…

Learn more

Robocath’s joint venture, Cathbot, concludes first clinical study in China to evaluate robotic PCI safety and efficacy

20 July 2022
End of study brings Robocath closer to commercializing R-One in China in 2023 149 patients enrolled over six months in four Chinese centers Results of first vascular robotics study on this scale in China will be published in March 2023

 

Rouen, France, July 20 2022 – Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, announces today that its joint venture, Cathbot, established in 2020…

Learn more

Robocath achieves positive results in R-Evolution multicenter European clinical study on robotic coronary angioplasty

18 May 2022
100% clinical success rate: zero complications linked to robot up to 30 days post-procedure >95% technical success rate 84.5% average reduction in physician radiation exposure

 

Rouen, France, May 18, 2022 – Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, today presents the results of its R-Evolution clinical study at the international EuroPCR conference. The study, which included 62 patients across six European centers,…

Learn more

Robocath concludes first European clinical study to demonstrate safety and efficacy of robotic coronary angioplasty performed with R-One

11 January 2022

Study results will be presented at EuroPCR conference in Paris, France, May 2022.

Rouen, France, January 11, 2022 – Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, announces today that it has concluded its ‘R-Evolution’ clinical study.

The study was aimed at assessing the safety and efficacy of the R-OneTM robotic assistance platform. Sixty-two patients across six European hospital centers participated: the university hospitals in Rouen and Caen with Prof. Durand…

Learn more

Robocath successfully completes first robotic coronary angioplasty with R-One™ in China

30 November 2021

Rouen, France, November 30, 2021 – Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, today announces the successful completion of the first coronary angioplasty in China assisted by its R-One™ robotic platform. The procedure took place at the 301 Hospital in Beijing on November 24; performed by Dr. Yundai Chen, a renowned interventional cardiologist and author of several scientific publications.

This robotic assisted procedure is the first intervention within a clinical…

Learn more

Robocath successfully performs first carotid stenting in France with R-One™ robot at Rennes University Hospital

24 November 2021

Rouen, France, November 24, 2021 – Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, announces today its successful first robotic carotid stenting at Rennes University Hospital. This breakthrough in the neurovascular field was performed on November 16, using Robocath’s R-One robot, operated by Dr. François Eugène and his team.

The procedure is part of a clinical study, which is the first stage of an ambitious research program launched last July by…

Learn more

Robocath and Rennes University Hospital launch co-development research program into treatment of strokes in partnership with Philips France

7 July 2021

Rouen and Rennes, France, July 7, 2021 – Robocath, a company that designs, develops and commercializes robotic solutions to treat cardiovascular diseases, and Rennes University Hospital, today announce the launch of a co-development research program using robotics to improve treatment for stroke victims.

With the support of Philips France, this unique program will be implemented over the next four years. It will focus on the use of robotics in treating strokes, the second most common cause of death…

Learn more
  • 1
  • 2
Subscribe to our newsletter